Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
D2.165 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Pediatric Asthma: A Cross-Sectional Study from Mexico City
D2.167 - Impact of body mass index on oscillometry parameters in children with respiratory symptoms
D2.168 - Impact of type two inflammation inflamation suppression on polyp burden in patients with nasal polyposis and concomitant asthma a comparative evaluation of biologic therapies
D2.171 - Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study
D2.172 - Effectiveness of Mepolizumab in patients with severe asthma and allergic rhinitis: Real-World Evidence from the TYREX Study
D2.173 - Real-World Evidence From the TYREX Study on the effectiveness of Mepolizumab in patients with severe asthma and clinically relevant aeroallergen sensitization
D2.174 - Association Between Environmental Conditions and Mold Sensitization in Children with Allergic Rhinitis and Asthma
D2.175 - Five-Year Real-World Outcomes of Mepolizumab Treatment in Severe Eosinophilic Asthma
D2.176 - Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma
D2.179 - Chronic cough triggered by industrialised milk and wheat products
D1.123 - Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy
D1.124 - Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study
D1.126 - Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design
D1.128 - Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series
D1.130 - Immune markers after one year treatment with benralizumab in severe eosinophilic asthma
D1.131 - Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation
Download the app
The congress at your fingertips
Available on
Download